Back to Search
OLIVER PRESS, M.D.
M.D.
Anatomic Pathology & Clinical Pathology Physician
NPI: 1235421710Individual
Specialties, Licenses & Credentials
Cytopathology Physician
Pathology — Cytopathology
Code: 207ZC0500X
A119630(CA)
Anatomic Pathology & Clinical Pathology PhysicianPrimary
Pathology — Anatomic Pathology & Clinical Pathology
Code: 207ZP0102X
A119630(CA)
Student in an Organized Health Care Education/Training Program
Student in an Organized Health Care Education/Training Program
Code: 390200000X
Research & Publications (20)
Gender-related survival differences associated with EGFR polymorphisms in metastatic colon cancer.
PMID 18413774·Cancer Res·2008
8-other
Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911.
PMID 16896003·J Clin Oncol·2006
3-trial
Radioimmunotherapy for non-Hodgkin's lymphomas: a historical perspective.
PMID 12728403·Semin Oncol·2003
7-preclinical
A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911.
PMID 12738671·Blood·2003
3-trial
Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease.
PMID 11709567·J Clin Oncol·2001
3-trial
A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts.
PMID 11588052·Blood·2001
4-observational
Immunotherapy of Non-Hodgkin's lymphomas.
PMID 11722986·Hematology Am Soc Hematol Educ Program·2001
6-review
A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas.
PMID 11049969·Blood·2000
3-trial
Principles of radioimmunotherapy for hematologists and oncologists.
PMID 11226002·Semin Oncol·2000
6-review
Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primates.
PMID 19515724·Blood·2009
4-observational
A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapy.
PMID 19182204·Blood·2009
7-preclinical
A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations.
PMID 19124831·Blood·2009
4-observational
Biodistributions, myelosuppression, and toxicities in mice treated with an anti-CD45 antibody labeled with the alpha-emitting radionuclides bismuth-213 or astatine-211.
PMID 19244101·Cancer Res·2009
7-preclinical
Pretargeted radioimmunotherapy using anti-CD45 monoclonal antibodies to deliver radiation to murine hematolymphoid tissues and human myeloid leukemia.
PMID 19118002·Cancer Res·2009
7-preclinical
131I anti-CD45 radioimmunotherapy effectively targets and treats T-cell non-Hodgkin lymphoma.
PMID 19332764·Blood·2009
7-preclinical
High-dose chemotherapy with BEAM or Busulphan/Melphalan and Thiotepa followed by hematopoietic cell transplantation in malignant lymphoma.
PMID 18949614·Leuk Lymphoma·2008
4-observational
Evidence mounts for the efficacy of radioimmunotherapy for B-cell lymphomas.
PMID 18854559·J Clin Oncol·2008
8-other
High-dose therapy and autologous stem cell transplantation for chemoresistant Hodgkin lymphoma: the Seattle experience.
PMID 18623377·Cancer·2008
3-trial
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells.
PMID 18509084·Blood·2008
3-trial
Radiolabeled and native antibodies and the prospect of cure of follicular lymphoma.
PMID 18586921·Oncologist·2008
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 3701 S HIGUERA ST
SAN LUIS OBISPO, CA 93401 - Phone
- (805) 546-0907
Quick Facts
- NPI
- 1235421710
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 3
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile